This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplement regimen. Dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
By MercyIowaCityClinics.org Editorial Staff | Last verified: July 2026
Clinical Ingredient Profile: Testosterone
- Classification: Endogenous steroid hormone (C19 steroid); pharmaceutical compound and prescription medication
- Primary Clinical Use: Testosterone replacement therapy (TRT) in hypogonadal males with clinical deficiency and symptomatic presentation (Strong evidence)
- Therapeutic Dose Range: 50–100 mg intramuscularly weekly or 2–10 mg transdermally daily (from FDA-approved TRT protocols)
- Typical Supplement Dose: Testosterone is not available as an over-the-counter dietary supplement in the United States; prescription forms include cypionate, enanthate, propionate, undecanoate, and transdermal gels/patches
- Preferred Form: Intramuscular testosterone cypionate or enanthate (longest half-life, stable pharmacokinetics); transdermal patches or gels for convenience and more physiologic dosing patterns
- Key Drug Interaction: Anticoagulants (warfarin, DOACs) — increased bleeding risk; insulin and oral hypoglycemics — enhanced glucose-lowering effects; corticosteroids — antagonistic effects on muscle protein synthesis
Clinical Overview
Testosterone is the primary male sex hormone and anabolic steroid synthesized in the testes (Leydig cells) and adrenal glands, with smaller quantities produced in ovaries and adipose tissue in women. As a pharmaceutical compound—not a dietary supplement—testosterone is available only by prescription and is FDA-approved for treating hypogonadism (abnormally low testosterone) in adult males with documented clinical deficiency and associated symptoms. The clinical evidence supporting testosterone replacement therapy in appropriately selected hypogonadal men is robust, but off-label use, supraphysiologic dosing, and unsupervised supplementation carry significant safety concerns. This profile evaluates testosterone through a clinical assessment framework, emphasizing the importance of diagnosis, monitoring, and risk stratification.
Pharmacological Profile
Testosterone is a C19 steroid synthesized from pregnenolone via the Delta5 pathway in the testes. Once secreted, approximately 98% of circulating testosterone binds to sex hormone-binding globulin (SHBG) or albumin; only 1–2% exists as free (bioavailable) testosterone. This free fraction crosses cell membranes and binds androgen receptors (ARs) in target tissues including skeletal muscle, bone, prostate, brain, and liver. Intracellular conversion by 5-alpha reductase produces dihydrotestosterone (DHT), a more potent androgen responsible for many androgenic effects, particularly in the prostate and hair follicles. Aromatase converts testosterone to estradiol in adipose and other peripheral tissues—a conversion critical for bone homeostasis and cardiovascular function in men.
Pharmacokinetically, exogenous testosterone's elimination half-life depends on formulation: intramuscular esters (cypionate, enanthate) persist 8–10 days; testosterone propionate requires more frequent dosing (3–4 days); transdermal formulations achieve steady-state levels within 24–48 hours. Hepatic metabolism via 17-ketosteroid reduction and 6-hydroxylation produces inactive metabolites excreted in urine. Renal and hepatic function influence clearance; impaired organ function prolongs elimination and increases toxicity risk.
Clinical Evidence Review
Testosterone Replacement in Hypogonadal Men
The strongest clinical evidence supports testosterone replacement in men with documented hypogonadism (serum testosterone <300 ng/dL) who present with clinical symptoms such as erectile dysfunction, decreased libido, fatigue, mood disturbance, and reduced muscle mass or strength. The Testosterone Trials (TTrials) cohort, a large prospective study enrolling over 700 hypogonadal men randomized to testosterone gel or placebo, demonstrated significant improvements in sexual function, energy levels, and quality-of-life measures at 12 months (Effect size d = 0.4–0.6 across domains). Intramuscular testosterone replacement improves lean body mass and strength in hypogonadal men; a meta-analysis of 19 RCTs (n = 816) found mean increases in lean mass of 1.6–3.2 kg and strength gains of 10–25% depending on concurrent resistance training. Bone mineral density improves modestly with testosterone replacement in hypogonadal men, though long-term fracture prevention data remain limited.
However, evidence also indicates potential cardiovascular risks. The Testosterone in Older Men with Mobility Limitations (TOM) trial was halted early when testosterone therapy in older men with mobility limitations showed increased cardiovascular event rates. Subsequent meta-analyses suggest associations between testosterone therapy initiation and acute cardiovascular events within the first 90 days of treatment, particularly in men over age 65 or those with pre-existing coronary artery disease. Prostate safety concerns include modest increases in prostate-specific antigen (PSA) levels during testosterone therapy; men with a history of prostate cancer generally should not receive testosterone replacement.
Athletic Performance and Supraphysiologic Dosing
Off-label testosterone use at supraphysiologic doses (300–3000 mg weekly or greater) to enhance athletic performance and muscle hypertrophy occurs outside clinical protocols and lacks ethical RCT evidence. Observational and case-series data indicate substantial muscle hypertrophy and strength gains, but are confounded by concurrent anabolic steroid use, resistance training intensity, nutrition, and genetic factors. Supraphysiologic testosterone carries documented harms: polycythemia, lipid dysregulation, liver enzyme elevations, gynecomastia (when aromatized to estradiol), testicular atrophy, azoospermia, mood changes, and accelerated cardiovascular atherosclerosis. The clinical evidence grade for performance enhancement remains Preliminary and ethically restricted; this application falls outside therapeutic medicine.
| Claimed Benefit | Evidence Level | Study Type | Clinical Dose |
|---|---|---|---|
| Hypogonadism symptom relief (sexual function, energy, mood) | Strong | Multiple RCTs, meta-analyses (TTrials, Testosterone in Men) | 50–100 mg/week IM or 2–10 mg/day TD |
| Lean muscle mass and strength in hypogonadal men | Strong | 19 RCTs, meta-analysis (n=816) | 50–100 mg/week IM or equivalent |
| Bone mineral density improvement | Moderate | RCTs and cohort studies | 50–100 mg/week IM or equivalent |
| Athletic performance at supraphysiologic doses | Preliminary (observational only) | Case series, observational; no RCTs | 300–3000 mg/week (non-clinical) |
| Cardiovascular safety in older men or those with CAD | Insufficient/Concerning | TOM trial (halted), meta-analyses | Therapeutic doses; events clustered in first 90 days |
Dosing Analysis: Clinical versus Over-the-Counter Context
A critical distinction must be emphasized: testosterone is not available as an over-the-counter dietary supplement in the United States. All testosterone formulations are FDA-approved prescription medications requiring medical evaluation, baseline hormone levels, and ongoing clinical monitoring. Prescription testosterone formulations deliver well-characterized doses. Intramuscular testosterone cypionate or enanthate typically dosed at 50–100 mg weekly achieves steady-state serum levels of 400–700 ng/dL (within or slightly above normal range). Transdermal testosterone patches and gels are dosed to mimic physiologic diurnal variation, typically delivering 2–10 mg daily to achieve serum levels of 400–700 ng/dL.
Supraphysiologic dosing (300 mg weekly or higher), used off-label for performance enhancement, dramatically exceeds clinical therapeutic ranges and produces serum testosterone levels of 1500–4000+ ng/dL. No clinical trial supports such dosing for non-disease applications. The dose gap between therapeutic TRT and performance-enhancement protocols reflects a critical risk-benefit shift: therapeutic replacement corrects deficiency; supraphysiologic dosing induces a pharmacologically induced hormonal state associated with documented organ toxicity and cardiovascular risks.
Bioavailability and Formulation Considerations
Testosterone's bioavailability depends entirely on formulation due to its lipophilic nature and rapid hepatic first-pass metabolism when administered orally. Oral testosterone undecanoate (Andriol) achieves reasonable bioavailability via lymphatic absorption when taken with fat; however, serum levels are variable and achievement of therapeutic levels often requires higher doses. Transdermal delivery systems (patches, gels, solutions) offer more predictable absorption and steady-state kinetics, though individual variability exists based on skin condition, site of application, and sweat production. Intramuscular esterified forms (cypionate, enanthate, propionate) provide depot delivery with sustained release; ester chain length inversely correlates with frequency of injection (propionate every 2–3 days; enanthate and cypionate every 7–10 days).
Bioavailability is further modulated by SHBG levels: elevated SHBG (from estrogen, thyroid hormone, liver disease) reduces free testosterone availability despite normal total levels; low SHBG increases free testosterone availability. Obesity increases aromatase activity, diverting testosterone to estradiol and reducing free testosterone bioavailability. These physiologic factors necessitate individualized assessment and dosing titration based on measured free and total testosterone levels, not standardized protocols alone.
Safety Profile and Drug Interactions
Adverse Effects at Therapeutic Doses
Testosterone replacement therapy at therapeutic doses is generally well-tolerated in appropriately screened men; however, specific monitoring is essential. Polycythemia (elevated hemoglobin and hematocrit) occurs in 10–25% of men on testosterone therapy, particularly with intramuscular formulations, and requires periodic blood count monitoring and dose reduction or phlebotomy if severe. Lipid dysregulation may occur, with reductions in HDL cholesterol and increases in LDL; men with dyslipidemia require baseline and periodic lipid panels. Hepatic enzyme elevations are uncommon at therapeutic doses but occur more frequently with 17-alpha-alkylated oral testosterone. Gynecomastia (breast tissue enlargement) results from excess aromatization of testosterone to estradiol; incidence ranges from 5–30% depending on baseline obesity and estrogen sensitivity. Testicular atrophy and suppression of endogenous testosterone and spermatogenesis occur during exogenous testosterone therapy; recovery may take months to over a year after discontinuation.
Mood changes, including increased aggression or irritability, occur in some users, particularly at supraphysiologic doses; however, therapeutic testosterone often improves mood and depression scores in hypogonadal men. Acne and male-pattern hair loss acceleration occur in genetically predisposed individuals due to DHT formation.
Contraindications and Drug Interactions
Absolute contraindications to testosterone therapy include documented or suspected prostate cancer, breast cancer in males, and severe untreated obstructive sleep apnea (testosterone may worsen apnea severity). Relative contraindications include uncontrolled polycythemia, uncontrolled hypertension, recent cardiovascular events, and active thrombotic disease.
Key drug interactions include anticoagulants (warfarin, apixaban, rivaroxaban) where testosterone may increase bleeding risk through effects on coagulation factors and platelet function; concurrent use requires careful INR or factor Xa monitoring. Insulin and oral hypoglycemics may require dose adjustment as testosterone enhances insulin sensitivity and glucose uptake. Corticosteroids show antagonistic effects on muscle protein synthesis and may reduce testosterone's anabolic benefits. Aromatase inhibitors (used to prevent gynecomastia) may be coadministered but require coordinated dosing to avoid over-suppression of estradiol, which is necessary for bone and cardiovascular health.
Clinical Recommendations and Patient Selection
Who May Benefit from Testosterone Replacement
Men with documented hypogonadism (serum testosterone <300 ng/dL) presenting with clinical symptoms (sexual dysfunction, decreased energy, mood changes, reduced muscle mass, decreased bone density) are appropriate candidates for testosterone replacement following comprehensive clinical and laboratory evaluation. Age alone is not a contraindication; however, men over 65 or those with pre-existing cardiovascular disease require careful risk-benefit assessment and more intensive cardiovascular monitoring. Young hypogonadal men (20–50 years) generally tolerate testosterone therapy well if monitored appropriately. Men seeking testosterone therapy for performance enhancement or cosmetic muscle gain in the absence of documented deficiency should be counseled regarding risks, legal restrictions, and lack of clinical evidence supporting efficacy.
Who Should Avoid Testosterone
Men with active prostate or breast cancer, untreated severe sleep apnea, acute myocardial infarction within the preceding three months, uncontrolled polycythemia, or thrombotic vascular disease should avoid testosterone therapy. Men with elevated prostate-specific antigen (PSA >4 ng/mL) or abnormal digital rectal